CTLA4 and cancer: Although co-enrichment of this signature was identified across other cancer types (Hugo et al. 2017), its expression was not associated with innate resistance to anti-CTLA-4 therapy, and thus far, correlation of the IPRES signature with resistance has not been found in other cohorts of patients treated with immune checkpoint blockade (Van Allen et al. 2015; Chen et al. 2016; Riaz et al. 2017).